Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
BlossomHill Therapeutics, Inc. (BLSM) had Consolidated Net Income/Loss of $-60.55M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-60.55M |
|
-- |
|
-- |
|
$64.02M |
|
$-64.02M |
|
$3.47M |
|
$-60.55M |
|
$-60.55M |
|
$-60.55M |
|
$-60.55M |
|
|
Consolidated Net Income/Loss |
$-60.55M |
$-60.55M |
|
$-64.02M |
|
$-63.58M |
|
2.44M |
|
2.44M |
|
$-24.83 |
|
$-24.83 |
|
| Balance Sheet Financials | |
$138.83M |
|
$1.73M |
|
$24.14M |
|
$162.97M |
|
$15.48M |
|
-- |
|
$22.39M |
|
$37.87M |
|
$-131.73M |
|
$125.09M |
|
$125.09M |
|
2.55M |
|
| Cash Flow Statement Financials | |
$-46.92M |
|
$-1.07M |
|
$84.53M |
|
$100.15M |
|
$136.68M |
|
$36.53M |
|
$1.09M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.97 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-47.99M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
45.97% |
|
-48.41% |
|
-37.16% |
|
-48.41% |
|
$49.08 |
|
$-19.68 |
|
$-19.25 |
|